Company Filing History:
Years Active: 2021-2024
Title: Innovations by Christophe Filippi in Cancer Treatment
Introduction
Christophe Filippi is an accomplished inventor based in Studio City, CA, with a focus on groundbreaking advancements in cancer treatment. He holds three patents that showcase his innovative contributions to the field of immunotherapy.
Latest Patents
His latest patents include "Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer." This patent describes IL2 engrafted into the CDR sequences of an antibody, which demonstrates preferred therapeutic profiles compared to existing clinical molecules. The compositions provided in this patent are designed to increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, these compositions offer improved half-life, stability, and producibility over recombinant human IL2 formulations such as Proleukin®. Another significant patent is "Antibody-cytokine engrafted proteins and methods of use for immune-related disorders." This invention provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high-affinity interleukin receptor. These proteins are intended to enhance anti-inflammatory cell responses and reduce pro-inflammatory effects in the treatment and prevention of immune-related disorders, including Type 1 Diabetes.
Career Highlights
Christophe Filippi is currently associated with Novartis AG, where he continues to push the boundaries of medical science through his innovative research and development efforts. His work has the potential to significantly impact the treatment landscape for various diseases.
Collaborations
He collaborates with talented professionals in his field, including Yaiza Diaz-De-Durana and Michael DiDonato, to further enhance the effectiveness of his inventions.
Conclusion
Christophe Filippi's contributions to the field of cancer treatment through his innovative patents highlight his commitment to advancing medical science. His work not only addresses critical health challenges but also paves the way for future breakthroughs in immunotherapy.